FDA-cleared profile

HealthCCSng

Zebra Medical Vision Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Non-invasive post-processing to evaluate calcified coronary plaques and estimate a coronary artery calcium category.

Clinical role
Software that automatically estimates a three-category coronary calcium detection category from existing non-cardiac-gated CT, with preview images, and outputs a result for radiologist review in parallel to standard workflow; not for stand-alone clinical decision-making.
Images and patients
CT/CTA · Heart/Cardiovascular; coronary arteries and calcified plaques
Key limitation
Keep in mind: Informational and non-diagnostic; not stand-alone for risk attribution or clinical decision-making; does not replace clinical assessment or independent final diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Non-invasive post-processing to evaluate calcified coronary plaques and estimate a coronary artery calcium category.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular; coronary arteries and calcified plaques Input: Existing adult non-cardiac-gated CT studies for patients older than 30, with the entire heart and at least one compliant series.
  • Who uses it?Intended users: Radiologists.
  • What does the software produce?Output: Estimated coronary calcium detection, Low/Medium/High category output, and representative annotated axial slices.
  • What is its most important limitation?Key limitation: Informational and non-diagnostic; not stand-alone for risk attribution or clinical decision-making; does not replace clinical assessment or independent final diagnosis.

Clinical takeaway. Clinical role: Non-invasive post-processing to evaluate calcified coronary plaques and estimate a coronary artery calcium category.

Evidence takeaway. Evidence from the reviewed source record: FDA-reported retrospective stand-alone validation of 447 anonymized chest CT cases from two institutions and multiple sites, using radiologist-majority reference categories.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Non-invasive post-processing to evaluate calcified coronary plaques and estimate a coronary artery calcium category.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Software that automatically estimates a three-category coronary calcium detection category from existing non-cardiac-gated CT, with preview images, and outputs a result for radiologist review in parallel to standard workflow; not for stand-alone clinical decision-making.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The HealthCCSng device analyzes existing non-cardiac-gated CT studies that include the heart of adult patients above the age of 30. The device generates a three-category output representing the estimated quantity of calcium detected together with preview axial images" … "analyzes cases using an artificial intelligence algorithm for the automated detection and estimation of coronary calcium and outputs a result for review by the radiologist. The device works in parallel to and in conjunction with the standard of care workflow.". Read from the exact FDA decision document on 2026-11-14.

Required input
Existing adult non-cardiac-gated CT studies for patients older than 30, with the entire heart and at least one compliant series.
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet input and population constraints.

Output and clinician action
Estimated coronary calcium detection, Low/Medium/High category output, and representative annotated axial slices.
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet output scope.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Radiologists.
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet intended-user statement.

Limitations
Informational and non-diagnostic; not stand-alone for risk attribution or clinical decision-making; does not replace clinical assessment or independent final diagnosis.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA limitation boundary.

Evidence summary
FDA-reported retrospective stand-alone validation of 447 anonymized chest CT cases from two institutions and multiple sites, using radiologist-majority reference categories.
  • Exact FDA submission
  • Checked 2026-09-19

Submission evidence only; not an independent clinical-performance claim.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA-reported retrospective stand-alone validation of 447 anonymized chest CT cases from two institutions and multiple sites, using radiologist-majority reference categories.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Submission evidence only; not an independent clinical-performance claim.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

HealthCCSng regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K210085
  • Samplen=447
  • IndependenceIndependence not established

K210085

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210085. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Existing adult non-cardiac-gated CT studies for patients older than 30, with the entire heart and at least one compliant series.

    Scope: Exact FDA submission. FDA packet input and population constraints.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K210085: HealthCCSng

  2. Routing

    Source context, not route validation: The exact FDA package describes HealthCCSng receiving non-cardiac-gated CT studies from Zebra's Imaging Analytics Platform (IMA) storage application and providing study analysis and results to IMA through an IMA integration feature. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "HealthCCSng receives a non-cardiac-gated CT study from the storage application, Zebra’s Imaging Analytics Platform (IMA)." … "IMA Integration feature: The study analysis and the results of a successful study analysis is provided to IMA.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K210085: HealthCCSng

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-09 ·

  4. Returned objects

    Source context, not route validation: Estimated coronary calcium detection, Low/Medium/High category output, and representative annotated axial slices.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K210085: HealthCCSng

  5. Viewer/worklist/report

    Unresolved route: Estimated coronary calcium detection, Low/Medium/High category output, and representative annotated axial slices.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K210085: HealthCCSng

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact FDA package describes HealthCCSng receiving non-cardiac-gated CT studies from Zebra's Imaging Analytics Platform (IMA) storage application and providing study analysis and results to IMA through an IMA integration feature. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "HealthCCSng receives a non-cardiac-gated CT study from the storage application, Zebra’s Imaging Analytics Platform (IMA)." … "IMA Integration feature: The study analysis and the results of a successful study analysis is provided to IMA.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for HealthCCSng; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K210085
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

FDA specifies non-cardiac-gated CT; CT/CTA is the controlled catalog enum and CTA is not implied.

Anatomy
Heart/Cardiovascular; coronary arteries and calcified plaques
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA coronary-artery scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2021-09-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K210085 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-09 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K210085: HealthCCSng

    U.S. Food and Drug Administration - Published 2021-09-15 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. HealthCCSng model card (K210085)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K210085

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K210085 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K260324

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

Canon Medical Informatics, Inc.

Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Modality
CT/CTA
Anatomy
Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
Decision
2026-05-22
FDA-cleared K253596

Aquilion ONE (TSX-308A/TSX-306A) V2.0

Canon Medical Systems Corporation

Authorized purpose: Canon Aquilion ONE V2.0 acquires and processes whole-body CT volumes, including head, chest, abdomen, pelvis, cardiac, extremity, inner-ear, and multi-energy examinations with the labeled reconstruction functions.

Modality
CT/CTA
Anatomy
Whole body; head; chest; abdomen; pelvis; heart; extremities; and inner ear
Decision
2026-05-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history